11th May 2006 10:26
Acambis PLC11 May 2006 Holding in Company Cambridge, UK and Cambridge, Massachusetts - 11 May 2006 - Acambis plc("Acambis") (LSE: ACM, NASDAQ: ACAM) announces that it received notification on10 May 2006 that as from 8 May 2006 Barclays PLC no longer held a notifiableinterest in the share capital of Acambis. -ends- Enquiries: Acambis plc Elizabeth Brown, Company Secretary Tel: +44 (0) 1223 275 300 Lyndsay Wright, VP, Communications and InvestorRelations About AcambisAcambis is a leading developer of vaccines to prevent and treat infectiousdiseases. Recognised internationally as the leading producer of smallpoxvaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,and is manufacturing emergency-use stockpiles of this investigational vaccinefor the US Government and other governments around the world. It is alsodeveloping an attenuated smallpox vaccine, MVA3000, under contracts with the USNational Institutes of Health. Acambis' US-based subsidiary Berna ProductsCorporation markets Vivotif(R), the world's only licensed oral typhoid vaccine,in North America. Acambis' investigational vaccine against Japaneseencephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also hasthe most advanced investigational vaccine against the West Nile virus, which hasspread to 48 US States in the last seven years, and a vaccine againstClostridium difficile bacteria, a leading cause of hospital-acquired infections. Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primarylisting is on the London Stock Exchange (ACM) and its shares are listed in theform of American Depositary Receipts on NASDAQ (ACAM). More information isavailable at www.acambis.com. "Safe Harbor" statement under the Private Securities Litigation Reform Act of1995: The statements in this news release that are not historical facts areforward-looking statements that involve risks and uncertainties, including thetiming and results of clinical trials, product development, manufacturing andcommercialisation risks, the risks of satisfying the regulatory approval processin a timely manner, the need for and the availability of additional capital. Fora discussion of these and other risks and uncertainties see "Risk management" inthe Company's 2004 Annual Report and "Risk factors" in its Form 20-F, inaddition to those detailed on the Company's website and in the Company's filingsmade with the Securities and Exchange Commission from time to time. Theseforward-looking statements are based on estimates and assumptions made by themanagement of Acambis and are believed to be reasonable, though are inherentlyuncertain and difficult to predict. Actual results or experience could differmaterially from the forward-looking statements. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Barclays